Compressed composition comprising magnesium salt
First Claim
1. A rapidly dissolving solid oral compressed composition comprising:
- a. one or more magnesium salts;
b. one or more hydrophilic polymers;
c. one or more disintegrants;
d. optionally one or more surfactants;
e. optionally one or more glidants;
f. optionally one or more fillers; and
g. optionally one or more lubricants;
h. wherein the composition provides a substantially stable dissolution profile when evaluated in vitro according to USP <
711>
for the one or more magnesium salts when the composition is stored for at least two months at 40°
C. and 75% relative humidity in a sealed container-enclosure system.
1 Assignment
0 Petitions
Accused Products
Abstract
An oral solid compress composition comprising a magnesium salt is provided. The composition provides a rapid dissolution of the magnesium salt, wherein not less than 75% of the magnesium salt dissolves within 45 minutes after placement in hydrochloric acid (0.1 N, 900 mL) as per USP Method <711>. In a particular embodiment, the magnesium salt is an inorganic salt such as MgO, Mg(OH)2, MgCl2, and others. The composition can be prepared by dry granulation, direct compression or another suitable process. The composition provides a substantially stable dissolution profile for the magnesium salt so that the dissolution profile changes only minimally even after an extended period of storage under pharmaceutically acceptable conditions when packaged in a sealed container-enclosure system. The solid composition may also exclude a cellulose-based composition. The compressed composition can be prepared and stored under anhydrous conditions.
-
Citations
58 Claims
-
1. A rapidly dissolving solid oral compressed composition comprising:
-
a. one or more magnesium salts;
b. one or more hydrophilic polymers;
c. one or more disintegrants;
d. optionally one or more surfactants;
e. optionally one or more glidants;
f. optionally one or more fillers; and
g. optionally one or more lubricants;
h. wherein the composition provides a substantially stable dissolution profile when evaluated in vitro according to USP <
711>
for the one or more magnesium salts when the composition is stored for at least two months at 40°
C. and 75% relative humidity in a sealed container-enclosure system. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
23. A solid oral dosage form comprising:
a. a compressed composition comprising;
i. one or more magnesium salts;
ii. one or more hydrophilic polymers;
iii. one or more disintegrants;
iv. optionally one or more surfactants;
v. optionally one or more glidants;
vi. optionally one or more fillers; and
vii. optionally one or more lubricants;
whereinviii. the composition provides a substantially stable dissolution profile when evaluated in vitro according to USP <
711>
for the one or more magnesium salts when the composition is stored for at least two months at 40°
C. and 75% relative humidity in a sealed container-enclosure system.- View Dependent Claims (24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
36. A compressed composition adapted for oral administration to a subject comprising:
-
a. one or more magnesium salts;
b. one or more hydrophilic polymers;
c. one or more disintegrants;
d. optionally one or more surfactants;
e. optionally one or more glidants;
f. optionally one or more fillers; and
g. optionally one or more lubricants;
whereinh. the magnesium salt is the only component present in a therapeutically effective amount;
i. the composition provides a substantially stable dissolution profile when evaluated in vitro according to USP <
711>
for the one or more magnesium salts when the composition is stored for at least two months at 40°
C. and 75% relative humidity in a sealed container-enclosure system; and
j. the composition contains less than 7.5% water. - View Dependent Claims (37, 38, 39, 40, 41, 42, 43)
-
-
44. A rapidly dissolving solid oral compressed composition comprising:
-
a. one or more magnesium salts;
b. one or more hydrophilic polymers;
c. one or more disintegrants; and
d. at least one or more of the following;
surfactant, glidant, filler, and lubricant;
whereine. the composition provides a substantially stable dissolution profile when evaluated in vitro according to USP <
711>
for the one or more magnesium salts when the composition is stored for at least two months at 40°
C. and 75% relative humidity in a sealed container-enclosure system;
f. the composition is prepared by a substantially anhydrous process; and
g. the magnesium salt is a sparingly soluble, slightly soluble, very slightly soluble, practically insoluble or insoluble salt. - View Dependent Claims (45, 46, 47, 48, 49, 50, 51)
-
-
52. A rapidly dissolving solid oral compressed composition comprising:
-
a. one or more magnesium salts selected from the group consisting of MgO, Mg(OH)2, MgF2, and Mg Carbonate;
b. one or more hydrophilic polymers;
c. one or more disintegrants; and
d. at least one or more of the following;
surfactant, glidant, filler, and lubricant;
whereine. the composition provides a substantially stable dissolution profile when evaluated in vitro according to USP <
711>
for the one or more magnesium salts when the composition is stored for at least two months at 40°
C. and 75% relative humidity in a sealed container-enclosure system;
f. the composition is prepared by a substantially anhydrous process;
g. the magnesium salt is a sparingly soluble, slightly soluble, very slightly soluble, practically insoluble or insoluble salt; and
h. the magnesium salt is the only component present in a therapeutically effective amount. - View Dependent Claims (53, 54, 55, 56, 57, 58)
-
Specification